Storia in 2 fonti

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

originale

endpoints.news1 mese fa

City Therapeutics gets $99M to gather data on three RNAi medicines

City Therapeutics raises $99.5M Series B to advance three RNAi candidates into the clinic and expand its delivery platform beyond the liver.

Leggi questa versione → originale

Timeline cronologica

lunedì 8 giugno 2026·biopharmadive.com
City banks nearly $100M for next-gen RNAi drugs
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon…
lunedì 8 giugno 2026·endpoints.news
City Therapeutics gets $99M to gather data on three RNAi medicines
City Therapeutics raises $99.5M Series B to advance three RNAi candidates into the clinic and expand its delivery platform beyond the liver.